Skip to main content
Log in

Clinical approach to treatable inborn metabolic diseases: An introduction

  • SSIEM SYMPOSIUM 2005
  • Published:
Journal of Inherited Metabolic Disease

Summary

In view of the major improvements in treatment, it has become increasingly important that in order for first-line physicians not to miss a treatable disorder they should be able initiate a simple method of clinical screening, particularly in the emergency room. We present a simplified classification of treatable inborn errors of metabolism in three groups. Group 1 includes inborn errors of intermediary metabolism that give rise to an acute or chronic intoxication. It encompasses aminoacidopathies, organic acidurias, urea cycle disorders, sugar intolerances, metal disorders and porphyrias. Clinical expression can be acute or systemic or can involve a specific organ, and can strike in the neonatal period or later and intermittently from infancy to late adulthood. Most of these disorders are treatable and require the emergency removal of the toxin by special diets, extracorporeal procedures, cleansing drugs or vitamins. Group 2 includes inborn errors of intermediary metabolism that affect the cytoplasmic and mitochondrial energetic processes. Cytoplasmic defects encompass those affecting glycolysis, glycogenosis, gluconeogenesis, hyperinsulinisms, and creatine and pentose phosphate pathways; the latter are untreatable. Mitochondrial defects include respiratory chain disorders, and Krebs cycle and pyruvate oxidation defects, mostly untreatable, and disorders of fatty acid oxidation and ketone bodies that are treatable. Group 3 involves cellular organelles and includes lysosomal, peroxisomal, glycosylation, and cholesterol synthesis defects. Among these, some lysosomal disorders can be efficiently treated by enzyme replacement or substrate reduction therapies. Physicians can be faced with the possibility of a treatable inborn error in an emergency, either in the neonatal period or late in infancy to adulthood, or as chronic and progressive symptoms – general (failure to thrive), neurological, or specific for various organs or systems. These symptoms are summarized in four tables. In addition, an extensive list of medications used in the treatment of inborn errors is presented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

3PGD:

3-phosphoglycerate dehydrogenase

BCAA:

branched-chain amino acid

BRBGD:

biotin-responsive basal ganglia disease

Cbl:

cobalamin

CDG:

congenital disorder of glycosylation

CPT I:

carnitine palmitoyltransferase type I

CPT II:

carnitine palmitoyltransferase type II

CTX:

cerebrotendinous xanthomatosis

FAO:

fatty acid oxidation

GTP:

guanosine triphosphate

HELLP:

haemolysis, elevated liver function, low platelets

HFI:

hereditary fructose intolerance

IE:

inborn error

IEM:

inborn error of metabolism

LPI:

lysinuric protein intolerance

HMG CoA:

3-hydroxy-3-methylglutaryl coenzyme A

IVA:

isovaleric acidaemia

LCHADD:

long-chain 3-hydroxy-acyl-CoA dehydrogenase deficiency

MCD:

multiple carboxylase deficiency

MMA:

methylmalonic acidaemia

MSUD:

maple syrup urine disease

MTHFR:

methylene tetrahydrofolate reductase

OA:

organic aciduria

OTC:

ornithine transcarbamylase

PA:

propionic acidaemia

PC:

pyruvate carboxylase

PDH:

pyruvate dehydrogenase

PKU:

phenylketonuria

PNPO:

pyridox(am)ine-5'-phosphate oxidase

PTP:

6-pyruvoyltetrahydropterin synthase

TFP:

trifunctional protein

TH:

tyrosine hydroxylase

TL:

carnitine acyltranslocase

UCD:

urea cycle disorders

VLCADD:

very long-chain acyl-CoA dehydrogenase deficiency

References

  • de Koning T (2006) Treatment with amino acids in serine deficiency disorders. J Inherit Metab Dis 29: 347–351.

    Google Scholar 

  • Junien C (2006) Impact of diets and nutrients/drugs on early epigenetic programming. J Inherit Metab Dis 29: 359–365.

    Google Scholar 

  • Kjaergaard S, Kristiansson B, Stibler H, et al (1998) Failure of short-term mannose therapy of patients with carbohydrate- deficient glycoprotein syndrome type 1A. Acta Paediatr 87: 884–888.

    Article  PubMed  CAS  Google Scholar 

  • Koga Y, Akita Y, Nishioka J, et al (2005) l-Arginine improves the symptoms of strokelike episodes in MELAS. Neurology 64: 710–712.

    PubMed  CAS  Google Scholar 

  • Mayatepek E, Schroder M, Kohlmuller D, et al (1997) Continuous mannose infusion in carbohydrate-deficient glycoprotein syndrome type I. Acta Paediatr 86: 1138–1140.

    PubMed  CAS  Google Scholar 

  • Ostman-Smith I, Brown G, Johnson A, et al (1994) Dilated cardiomyopathy due to type II X-linked 3-methylglutaconic aciduria: successful treatment with pantothenic acid. Br Heart J 72: 349–353.

    PubMed  CAS  Google Scholar 

  • Quinzii C, Naini A, Salviati L, et al (2006) A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary Coenzyme Q10 deficiency. Am J Hum Genet 78: 345–349.

    Article  PubMed  CAS  Google Scholar 

  • Raine DN (ed.) (1975) The Treatment of Inherited Metabolic Disease. Lancaster: Medical and Technical Publishing.

  • Roe CR, Mochel F (2006) Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential. J Inherit Metab Dis 29: 332–340.

    Google Scholar 

  • Saudubray JM, Desguerre I, Sedel F, Charpentier C (2006) A clinical approach to inherited metabolic disorders. In: Fernandes J, Saudubray JM, van den Berghe G, Walter J, eds. Inborn Metabolic Diseases: Diagnosis and Treatment, 4th edn. Berlin: Springer-Verlag, 2006 in press.

    Google Scholar 

  • Valayannopoulos V, Verhoeven NV, Mention K, et al (2006) Transaldolase deficiency: a new cause of hydrops foetalis and neonatal multiorgan disease. J Pediatr, in press.

  • Van Spronsen FJ, Smit GPA, Erwich JJHM (2005) Inherited metabolic diseases and pregnancy. BJOG Int J Obstet Gynaecol 112: 2–11.

    Article  CAS  Google Scholar 

  • Walter JH, Wraith J (2006) Treatment: present status and new trends. In: Fernandes J, Saudubray JM, van den Berghe G, Walter J, eds. Inborn Metabolic Diseases: Diagnosis and Treatment. Berlin: Springer-Verlag, 4th edition, in press.

    Google Scholar 

  • Zeng WQ, Al Yamani E, Acierno JS Jr, et al (2005) Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3. Am J Hum Genet 77: 16–26.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J.-M. Saudubray.

Additional information

Communicating editor: Jean-Marie Saudubray

Competing interests: None declared

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saudubray, JM., Sedel, F. & Walter, J.H. Clinical approach to treatable inborn metabolic diseases: An introduction. J Inherit Metab Dis 29, 261–274 (2006). https://doi.org/10.1007/s10545-006-0358-0

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10545-006-0358-0

Keywords

Navigation